Start with the number that frames the scale: 210,625. That is the product quantity listed on an FDA drug enforcement record, numbered D-0554-2026, for a recall of single-dose lidocaine injection ampules by Spectra Medical Devices, LLC. The reason is one of the most consequential phrases in pharmaceutical manufacturing — a lack of assurance of sterility — and for an injectable drug it carries weight that the same words would not for a tablet. The record comes from openFDA, the agency's public enforcement dataset.
The product is Lidocaine HCl Injection USP, supplied in 25-count cartons of 5 mL single-dose ampules, prescription only, with the record noting it was made in South Korea and distributed by Spectra Medical Devices of Wilmington. Lidocaine is a workhorse local anesthetic, used across clinics, dental offices, and hospitals to numb tissue for procedures. Injectable lidocaine is delivered straight into or beneath the skin and tissue, which is exactly why the sterility question is so pointed: anything that bypasses the body's outer defenses has to be sterile, full stop.
"Lack of Assurance of Sterility"— openFDA drug enforcement, source
The phrasing in the record is precise and worth parsing, because the distinction is the whole story. 'Lack of assurance of sterility' is not the same statement as 'these ampules are contaminated.' It means the manufacturer or the FDA cannot be confident, based on the manufacturing and quality records, that every unit in the affected lots meets the sterility standard an injectable must meet. The defect is in the assurance — the documented chain of evidence and process controls that guarantees sterility — rather than necessarily in a confirmed finding of microbes in a given vial. For injectables, that distinction does not soften the response: if sterility cannot be assured, the product cannot be trusted, and it comes off the market.
Why injectables are held to a different standard
The reason sterility assurance is treated as load-bearing for injectables comes down to the route of administration. An oral drug passes through the stomach and gut, which present real barriers to many contaminants. An injection delivers the drug past those barriers, directly into tissue or the bloodstream. A sterility failure in an injectable therefore raises the specter of introducing bacteria or fungi where the body has little defense — the kind of event that can cause local or systemic infection. That is why sterile-injectable manufacturing is among the most tightly controlled processes in the industry, governed by exacting standards for the manufacturing environment, the equipment, and the testing that releases each lot.
It is also why sterility-assurance problems are a recurring theme in the enforcement data for injectables specifically. When the documented assurance breaks down — whether through a process deviation, an environmental-monitoring lapse, or a gap in the records that prove sterility — the conservative and correct action is to recall, even absent a confirmed contamination or a reported patient harm. The standard is precautionary by design.
What the record says about the action
The enforcement record describes this as a voluntary, firm-initiated recall, meaning Spectra Medical Devices began the action itself rather than being compelled by the FDA. The status is listed as ongoing, indicating it was still in progress as of the report. The record's classification places it in the FDA's hazard tiering; readers checking the listing can see exactly which class the agency assigned, which signals how the agency weighs the potential for harm.
For the clinics, pharmacies, and hospitals that stock injectable lidocaine, the practical response to a sterility-assurance recall is straightforward: identify whether your inventory matches the recalled product and lots, quarantine those units, and follow the recall instructions rather than administering anything from an affected lot. Because the affected product is prescription-only and used in professional settings, the front line here is institutional purchasers and clinicians, not retail consumers — another reason the precise product description and lot information in the FDA record matter for tracing the recall accurately.
The broader signal in the data is about how the system is meant to work. A large-volume recall of a common sterile injectable — over 210,000 ampules — sounds alarming as a headline, but the enforcement record reframes it: a manufacturer flagged a sterility-assurance gap and pulled the product before any confirmed harm was established, and the action is documented publicly with its reason, quantity, and status. That is the precautionary standard for injectables doing exactly what it is supposed to do.
It is also worth noting where this product sits in the supply chain, because that context shapes the impact. The record describes the ampules as made in South Korea and brought to the U.S. market through a domestic distributor. That arrangement is routine for generic sterile injectables, a category long marked by global manufacturing and, periodically, by shortages. Lidocaine and other staple anesthetics and emergency drugs are produced by a relatively small number of facilities, so a large-volume recall can do more than create a safety event — it can tighten supply of a product clinicians rely on daily. The enforcement record does not speak to availability, but readers tracking the sterile-injectable market know that recall and shortage often travel together.
That linkage is one reason sterility-assurance recalls draw scrutiny beyond the immediate safety question. When a high-volume lot of a common anesthetic comes off the market, purchasers have to find substitutes, and substitution in a constrained category is not always quick. The precautionary standard that drives the recall is the right call — an injectable whose sterility cannot be assured should not be used — but the downstream effect on supply is a real cost that the system absorbs in exchange for that safety margin. Seeing the quantity on the record, 210,625 ampules, is what makes that trade-off concrete rather than abstract.
Anyone needing to confirm whether specific lots are affected can consult the FDA's drug enforcement records directly, where this recall — D-0554-2026 — is listed with its full product description, reason, quantity, classification, and status. For an injectable, verifying against the record is not optional diligence; it is the point of having the record.